Scott D Patterson
Overview
Explore the profile of Scott D Patterson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
4019
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Raghu G, Brown K, Collard H, Cottin V, Gibson K, Kaner R, et al.
Lancet Respir Med
. 2016 Dec;
5(1):22-32.
PMID: 27939076
Background: Lysyl oxidase-like 2 (LOXL2) catalyses collagen cross-linking and is implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The aim of this study was to investigate the efficacy and...
12.
Pillai R, Lopategui J, Dhall D, Guindi M, Slavin T, Lofton-Day C, et al.
Adv Anat Pathol
. 2016 Feb;
23(2):92-103.
PMID: 26849815
The number of molecular biomarkers to inform treatment decisions in patients with metastatic colorectal cancer (mCRC) continues to expand and with it the methodologies that can be employed to evaluate...
13.
Hoofnagle A, Whiteaker J, Carr S, Kuhn E, Liu T, Massoni S, et al.
Clin Chem
. 2016 Jan;
62(1):48-69.
PMID: 26719571
Background: For many years, basic and clinical researchers have taken advantage of the analytical sensitivity and specificity afforded by mass spectrometry in the measurement of proteins. Clinical laboratories are now...
14.
van Krieken J, Rouleau E, Ligtenberg M, Normanno N, Patterson S, Jung A
Virchows Arch
. 2015 Nov;
468(4):383-96.
PMID: 26573425
Personalized medicine shows promise for maximizing efficacy and minimizing toxicity of anti-cancer treatment. KRAS exon 2 mutations are predictive of resistance to epidermal growth factor receptor-directed monoclonal antibodies in patients...
15.
Peeters M, Oliner K, Price T, Cervantes A, Sobrero A, Ducreux M, et al.
Clin Cancer Res
. 2015 Sep;
21(24):5469-79.
PMID: 26341920
Purpose: We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil,...
16.
Patterson S, Rossi J, Paweletz K, Fitzpatrick V, Begley C, Busse L, et al.
PLoS One
. 2015 Mar;
10(3):e0122149.
PMID: 25807104
Several clinical trials in oncology have reported increased mortality or disease progression associated with erythropoiesis-stimulating agents. One hypothesis proposes that erythropoiesis-stimulating agents directly stimulate tumor proliferation and/or survival through cell-surface...
17.
Chen K, Yang D, Li X, Sun B, Song F, Cao W, et al.
Proc Natl Acad Sci U S A
. 2015 Jan;
112(4):1107-12.
PMID: 25583476
Gastric cancer (GC) is a highly heterogeneous disease. To identify potential clinically actionable therapeutic targets that may inform individualized treatment strategies, we performed whole-exome sequencing on 78 GCs of differing...
18.
Laterza O, Plump A, Ming J, Richards S, Burczynski M, Wagner J, et al.
Clin Chem
. 2014 Nov;
61(4):579-83.
PMID: 25376580
No abstract available.
19.
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience
Bass M, Yao B, Hei Y, Ye Y, Davis G, Davis M, et al.
PLoS One
. 2014 Oct;
9(10):e108048.
PMID: 25314641
Purpose: We sought to develop placental growth factor as a predictive pharmacodynamic biomarker for motesanib efficacy as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer. Experimental Design: Placental...
20.
Douillard J, Oliner K, Siena S, Tabernero J, Burkes R, Barugel M, et al.
N Engl J Med
. 2013 Sep;
369(11):1023-34.
PMID: 24024839
Background: Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be...